Bitget App
Mag-trade nang mas matalino
Buy cryptoMarketsTradeFuturesEarnSquareMore

HKEX:2637 stock price forecast

How will HKEX:2637 stock perform in 2026 and 2030?

This page primarily displays the projected price range for HKEX:2637 stock over the next 12 months, as well as trading recommendations for the next three months. This data is based on the historical performance of HKEX:2637, the development trends of Fujian Haixi Pharmaceuticals Co., Ltd. Class H, and a summary of analysis reports from major international investment banks and Wall Street research institutions, along with price analyses and forecasts from well-known analysts on platforms such as TradingView and Reddit. Together, these sources form a comprehensive market outlook for HKEX:2637. The forecast includes potential high, median, and low price scenarios to help users understand possible future price movements across different time horizons.

This page combines Fujian Haixi Pharmaceuticals Co., Ltd. Class H's financial performance and industry trends to provide short-term price predictions for HKEX:2637 stock over the next one to two years, as well as long-term price predictions extending to 2030.

The data is updated regularly as new market information becomes available. The information on this page is for reference only and does not constitute investment advice.

1-year HKEX:2637 stock price forecast

Price target:
168.83 HKD
+21.72%
Based on 1-year price forecasts from 69 analysts, the highest estimate is 211.86 HKD, while the lowest estimate is 104.07 HKD.

Analyst rating for HKEX:2637

Based on ratings from 43 analysts over the past three months, the overall consensus is Hold.

Strong buy
15
Buy
7
Hold
8
Sell
4
Strong sell
9

FAQ

How has HKEX:2637's EPS performed recently?

HKEX:2637's EPS is projected to reach -- HKD next quarter. Explore more Fujian Haixi Pharmaceuticals Co., Ltd. Class H financial data and stay up to date on the company's latest developments on the HKEX:2637 stock details page.

What is the revenue forecast for HKEX:2637 next quarter?

Fujian Haixi Pharmaceuticals Co., Ltd. Class H's revenue is projected to reach -- HKD in the next quarter. You can view Fujian Haixi Pharmaceuticals Co., Ltd. Class H's revenue and earnings on the HKEX:2637 stock details page.

What is the price target for HKEX:2637?

Based on analyst estimates, the most likely target price for HKEX:2637 over the next 12 months is 168.83 HKD, with a projected high of 211.86 HKD and a projected low of 104.07 HKD. To track whether this target is reached within the next year, you can view the HKEX:2637 stock price chart on the HKEX:2637 stock details page to check the current HKEX:2637 stock price, or follow the latest developments related to HKEX:2637 on the HKEX:2637 Stock News page.

What is the analyst rating for HKEX:2637?

We collected ratings from 43 analysts who have evaluated HKEX:2637 stock over the past three months. Most analysts maintain a Hold outlook, and after aggregating all opinions, the overall consensus rating is Hold. Please note that this information does not constitute trading advice. You should still conduct your own research.

What is the projected price of HKEX:2637 stock in 2030?

Based on price forecasts and analyses of Fujian Haixi Pharmaceuticals Co., Ltd. Class H from Wall Street analysts and major investment banks, HKEX:2637 is projected to trade between 277.40 HKD and 1387.00 HKD in 2030.

HKEX:2637 stock price change

Sa huling araw ng trading, HKEX:2637 sarado ang stock sa 138.70 HKD, na may pagbabago sa presyo ng 1.61% para sa araw.

Trade stock futuresHKEX:2637 stock details

Tungkol kay Bitget

Ang unang Universal Exchange (UEX) sa mundo, na nagbibigay-daan sa mga gumagamit na mag-trade hindi lamang ng mga cryptocurrency, kundi pati na rin ng mga stock, ETF, forex, gold, at mga real-world asset (RWA).
Learn more
HKEX/
HKEX:2637 stock price forecast